Sign In
Buy APLS
$41.03
+0 (+0%)
At Close: Jun 03, 2026
Apellis' (APLS) Q3 Earnings Miss Estimates, Revenues Top Mark
12:47pm, Tuesday, 08'th Nov 2022
Apellis' (APLS) earnings miss estimates in the third quarter of 2022 while revenues beat the same.
Apellis Pharmaceuticals, Inc. (APLS) Q3 2022 Earnings Call Transcript
01:26am, Tuesday, 08'th Nov 2022
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q3 2022 Earnings Conference Call November 7, 2022 4:30 PM ET Company Participants Adam Townsend - Chief Commercial Officer Cedric Francois - Co-Founder, Pr
Apellis Pharmaceuticals, Inc. (APLS) Reports Q3 Loss, Tops Revenue Estimates
06:56pm, Monday, 07'th Nov 2022
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -18.24% and 11.28%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead fo
Apellis Pharma Crashes On Unexpected Delay For Eye Drug — A Boon For Iveric Bio
10:06am, Friday, 04'th Nov 2022
Apellis reported an unexpected delay for its eye-disease treatment, leading APLS stock to crash as shares of rival Iveric Bio inched higher. The post Apellis Pharma Crashes On Unexpected Delay For Eye
Is a Surprise Coming for Apellis (APLS) This Earnings Season?
09:47am, Friday, 04'th Nov 2022
Apellis (APLS) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Robust improvements in key markers of disease sustained across a broad population of adults with paroxysmal nocturnal hemoglobinuria (PNH) Robust improvements in key markers of disease sustained acros
Apellis Pharmaceuticals to Host Conference Call on Nov 7, 2022 to Discuss Third Quarter 2022 Financial Results
04:05pm, Monday, 31'st Oct 2022
WALTHAM, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will hos
Apellis' (APLS) Empaveli Aids Growth, Stiff Competition a Woe
12:02pm, Monday, 10'th Oct 2022
Apellis' (APLS) lead drug, Empaveli, is approved for treating paroxysmal nocturnal hemoglobinuria. The drug's label expansion studies hold promise.
Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Performers Today
12:22pm, Monday, 03'rd Oct 2022
Apellis and Belite Bio were among the worst-performing biotech stocks Monday after presenting test results in two eye diseases. The post Why Top-Rated Biotechs Apellis, Belite Are Among The Worst Perf
Apellis Pharmaceuticals Announces New Presentation Time at the Bank of America Global Healthcare Conference
04:05pm, Monday, 12'th Sep 2022
WALTHAM, Mass., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced updated timing for its f
Why Is Apellis Pharmaceuticals, Inc. (APLS) Down 9.8% Since Last Earnings Report?
12:48pm, Wednesday, 07'th Sep 2022
Apellis Pharmaceuticals, Inc. (APLS) reported earnings 30 days ago. What's next for the stock?
Apellis Pharmaceuticals to Present at Upcoming Investor Conferences
07:00am, Thursday, 01'st Sep 2022
WALTHAM, Mass., Sept. 01, 2022 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals , Inc. (Nasdaq: APLS), a global biopharmaceutical company and leader in complement, today announced that the company will pa
Apellis (APLS) Q2 Earnings and Sales Miss Estimates, Stock Down
01:32pm, Tuesday, 09'th Aug 2022
Apellis' (APLS) missed earnings and sales estimates in the second quarter of 2022. Consequently, the stock declines.
Apellis Pharmaceuticals, Inc. (APLS) CEO Cedric Francois on Q2 2022 Results - Earnings Call Transcript
10:22pm, Monday, 08'th Aug 2022
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS ) Q2 2022 Earnings Conference Call August 8, 2022 4:30 PM ET Company Participants Meredith Kaya - SVP, IR & Strategic Finance Adam Townsend - Chief Commercia
Apellis Pharmaceuticals, Inc. (APLS) Reports Q2 Loss, Misses Revenue Estimates
06:48pm, Monday, 08'th Aug 2022
Apellis Pharmaceuticals, Inc. (APLS) delivered earnings and revenue surprises of -2.10% and 4.90%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the s
